Aberdeen Group
SUPN icon

Aberdeen Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Aberdeen Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Buy
453,206
+177,645
+64% +$8.53M 0.03% 426
2026
Q1 		$14.2M Buy
275,561
+3,987
+1% +$203K 0.02% 512
2025
Q4 		$13.5M Buy
+271,574
New +$13.2M 0.02% 547

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Aberdeen Group's SUPN Position: Q2 2026 in Review

Aberdeen Group increased its Supernus Pharmaceuticals (SUPN) stake by 64% in Q2 2026, buying an estimated $8.53M and bringing the position to 453,206 shares worth $21.1M. The position accounts for 0.03% of the portfolio, ranked #426.

Aberdeen Group first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Aberdeen Group held 453,206 shares of Supernus Pharmaceuticals worth $21.1M as of Q2 2026.
  • Aberdeen Group bought 177,645 Supernus Pharmaceuticals shares in Q2 2026, an estimated $8.53M.
  • Supernus Pharmaceuticals made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #426 holding.
  • Aberdeen Group first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.